Hematologic Malignancy
High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements
CI-CAN-00009268DHLExplore in graph →
Hematologic21 active trials
- NCIt
- C125904
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009268DHLExplore in graph →
Clinical trials
31 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06536049 | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 38 | Yazeed SawalhaOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05755087 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | recruiting | Phase 1 | 18 | Lapo AlinariOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05908409 |
| A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies(CASSANDRA) |
| recruiting |
| Phase 1 / Phase 2 |
| 37 |
| IDP Discovery Pharma S.L.INDUSTRY |
| 1 |
| May 1, 2025 |
| clinicaltrials |
Data updated 23 days agoSource updated Aug 25, 2026source: clinicaltrials